Author

Ulrike Hermes

Observed names: Hermes, Ulrike, U. Hermes

Institution: Federal Institute for Drugs and Medical Devices

Observed institution: Federal Institute for Drugs and Medical Devices

OpenAlex ID: A5047837005

Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective

2014 · Niels Eckstein, Lea Röper, et al. · Journal of Experimental & Clinical Cancer Research · 44

Licensing of Orphan Medicinal Products—Use of Real-World Data and Other External Data on Efficacy Aspects in Marketing Authorization Applications Concluded at the European Medicines Agency Between 2019 and 2021

2022 · Frauke Naumann-Winter, Franziska Wolter, et al. · Frontiers in Pharmacology · 13

Tyrosine kinase inhibitors becoming generic drugs – risks and chances from a regulatory perspective

2014 · Niels Eckstein, Lea Röper, et al. · Generics and Biosimilars Initiative Journal · 2

Herausforderungen komplexer Studiendesigns bei der Zulassung von neuen Onkologika aus Sicht des BfArM

2021 · Martin Mengel, Claudia Riedel, et al. · Forum

357 INVITED The Regulatory Perspective of Co-Development of Investigational Agents

2011 · F. Pignatti, U. Hermes, et al. · European Journal of Cancer

Works count: 6

Citation count: 59

H-index: 2

I10-index: 2